Shawn Cazzell, DPM
Podiatrist · Fresno, CANPI 1629392568
Payments from drug & device makers
Across 79 payments — averaging $9969.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$224K
- Organogenesis Inc.$191K
- Ipsen Innovation$102K
- Acell, Inc.$83K
- Globus Medical$67K
- Endo Pharmaceuticals Inc.$58K
- plus $62K from 8 others
Across 8 payments — averaging $15,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Integra Lifesciences Corporation$123K
- Acell, Inc.$5K
What the payments were for
- Consulting fees$18,937100%
- Food & beverage$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 21 | $223,643 |
| Organogenesis Inc. | 13 | $190,842 |
| Ipsen Innovation | 9 | $102,200 |
| Acell, Inc. | 1 | $83,356 |
| Globus Medical | 5 | $66,993 |
| Endo Pharmaceuticals Inc. | 16 | $58,243 |
| Mallinckrodt Hospital Products Inc. | 7 | $39,890 |
| Royal Biologics, Inc. | 1 | $10,537 |
| Biotissue Holdings Inc. | 1 | $7,500 |
| Polynovo North America LLC | 1 | $2,400 |
| Bristol Myers Squibb | 1 | $1,000 |
| Medtronic | 1 | $900 |
| Amnio Technology, LLC | 1 | $45 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fibrinet$10,537
- INTELLIS ADAPTIVESTIM$900
How this compares
$787,576 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $214 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Fresno
- Emmy OjiFresno$29K
- Robert BuckenbergerFresno$21K
- Fardin HakakianTarzana$2.8M
- David GuzmanNapa$2.1M
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.6M
- David ArmstrongLos Angeles$1.4M
- Dean VayserCarlsbad$1.2M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.